Clinical bottom line
Biodegradable polymer-based scaffolds represent a promising adjunct for reconstructing large segmental bone defects, offering a temporary matrix that supports cellular infiltration and new bone formation while gradually degrading to allow native tissue replacement. Recent advances in scaffold design, including 3D printing and bioactive polymer conjugation, have improved their mechanical properties and osteoinductive potential. However, clinical translation remains limited by challenges in replicating native bone biomechanics, ensuring vascularization, and controlling degradation rates. Current evidence is largely preclinical or early-phase, warranting cautious optimism and further validation before routine clinical adoption.
What the evidence shows
Large segmental bone defects pose a significant reconstructive challenge due to the need for structural support and biological stimulation for bone regeneration. Biodegradable polymer-based scaffolds, particularly those fabricated from poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) and other bioactive polymers, have been extensively studied as bone tissue engineering platforms (Naznin et al., 2013). These scaffolds provide a porous, three-dimensional framework facilitating osteoblast attachment, proliferation, and differentiation, while their biodegradability obviates the need for secondary removal surgery.
Gilissen et al. (2026) reviewed recent developments in 3D printed scaffolds for segmental long bone defects, highlighting that additive manufacturing enables patient-specific scaffold geometries with controlled porosity and mechanical strength approximating native bone. This customization enhances scaffold integration and load-bearing capacity, critical for large defect reconstruction. Furthermore, Yuan et al. (2023) demonstrated that conjugated bioactive polymers incorporated into 3D bionic scaffolds can promote osteogenesis and accelerate bone defect repair in preclinical models, suggesting enhanced biological performance over inert polymers.
The fabrication techniques, including selective laser sintering and nano-cellulose reinforcement, have improved scaffold mechanical properties and degradation profiles (Naznin et al., 2012; unpublished sources). These advances address prior limitations of polymer brittleness and unpredictable resorption rates. The interconnected porous architecture supports vascular ingrowth, a key factor for successful bone regeneration.
Caveats and uncertainty
Despite encouraging preclinical data, clinical evidence for biodegradable polymer scaffolds in large bone defect reconstruction remains sparse. Most studies are limited to animal models or in vitro assessments, with few controlled human trials available. The long-term mechanical stability of these scaffolds under physiological load is not fully established, raising concerns about early scaffold failure or insufficient support during critical healing phases.
Biodegradation kinetics must be finely tuned; premature scaffold resorption can compromise structural integrity, whereas delayed degradation may impede natural bone remodeling. Additionally, scaffold-induced inflammatory responses and potential immunogenicity require further characterization. Vascularization within large constructs remains a significant hurdle, as inadequate blood supply can limit cell survival and bone formation.
Manufacturing reproducibility and regulatory approval pathways for complex bioactive scaffolds are also challenges that may delay widespread clinical implementation. Cost-effectiveness compared to established techniques such as autografts or allografts has not been conclusively demonstrated.
How this may change practice
If ongoing research confirms safety and efficacy, biodegradable polymer-based scaffolds could become a valuable tool for orthopedic surgeons managing large segmental bone defects, particularly when autograft availability is limited or donor site morbidity is a concern. The ability to customize scaffold architecture via 3D printing may facilitate personalized reconstruction strategies, improving functional outcomes.
Integration of bioactive molecules and cells into these scaffolds may further enhance osteoinductive capacity, potentially reducing healing times and complication rates. However, until robust clinical data emerge, these scaffolds should be considered investigational and used within controlled trial settings or specialized centers.
Orthopedic clinicians should remain informed about advances in scaffold materials and fabrication technologies, as these may soon complement or partially replace traditional grafting methods. Multidisciplinary collaboration with bioengineers and regulatory experts will be essential to translate these innovations into routine practice.